Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study

Background: Potential novel strategies for adverse event (AE) management of osimertinib therapy, including therapeutic drug monitoring and the use of biomarkers, have not yet been fully investigated. This study aimed to evaluate (1) the relationship between exposure to osimertinib, especially its ac...

Descripción completa

Detalles Bibliográficos

Autores principales:	Ishikawa, Emi, Yokoyama, Yuta, Chishima, Haruna, Kasai, Hidefumi, Kuniyoshi, Ouki, Kimura, Motonori, Hakamata, Jun, Nakada, Hideo, Suehiro, Naoya, Nakaya, Naoki, Nakajima, Hideo, Ikemura, Shinnosuke, Kawada, Ichiro, Yasuda, Hiroyuki, Terai, Hideki, Jibiki, Aya, Kawazoe, Hitoshi, Soejima, Kenzo, Muramatsu, Hiroshi, Suzuki, Sayo, Nakamura, Tomonori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030409/ https://www.ncbi.nlm.nih.gov/pubmed/36637703 http://dx.doi.org/10.1007/s10637-023-01328-9